XML 35 R14.htm IDEA: XBRL DOCUMENT v2.4.1.9
Summary of Significant Accounting Polices (Concentration of Royalty Income) (Narrative) (Details) (USD $)
 12 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Royalty income $ 427,000us-gaap_RoyaltyRevenue $ 268,000us-gaap_RoyaltyRevenue
Royalty Revenue - Arthrex    
Royalty income $ 427,000us-gaap_RoyaltyRevenue
/ us-gaap_ConcentrationRiskByTypeAxis
= us-gaap_RevenueFromRightsConcentrationRiskMember		 $ 268,000us-gaap_RoyaltyRevenue
/ us-gaap_ConcentrationRiskByTypeAxis
= us-gaap_RevenueFromRightsConcentrationRiskMember
Concentration Risk, Royalty Agreement

On January 24, 2011, the Company entered into an Asset Purchase Agreement with Arthrex (the agreement being the "Arthrex Asset Purchase Agreement"), pursuant to which the Company agreed to sell the assets of the Reconstructive Division to Arthrex. The Arthrex Asset Purchase Agreement also provides for the Company to receive royalty payments equal to 5% of net sales of the Company's products made by Arthrex on a quarterly basis for a term up to and including the 20th anniversary of the closing date.